Pseudorabies virus (PrV) is the etiological agent of Aujeszky's disease, a disease that causes heavy economic losses in the swine industry. A rational approach to the generation of an effective vaccine against this virus requires an understanding of the immune response induced by it and of the role of the various viral antigens in inducing such a response. We have constructed mutants of PrV [strain PrV(Ka)] that differ from each other only in expression of the viral nonessential glycoproteins gI, gp63, gX, and glll (i.e., are otherwise isogenic).
only in expression of the viral nonessential glycoproteins gI, gp63, gX, and glll (i.e., are otherwise isogenic).
These mutants were used to ascertain the importance of each of the nonessential glycoproteins in eliciting a PrV-specific cytotoxic T-lymphocyte (CTL) response in mice and pigs. Immunization of DBA/2 mice and pigs with a thymidine kinase-deficient (TK-) mutant of PrV elicits the formation of cytotoxic cells that specifically lyse syngeneic infected target cells. These PrV-specific cytolytic cells have the phenotype of major histocompatibility complex class I antigen-restricted CTLs. The relative number of CTLs specific for glycoproteins gI, gp63, gX, and gIll induced in mice vaccinated with a TK-mutant of PrV was ascertained by comparing their levels of cytotoxicity against syngeneic cells infected with either wild-type virus or gI-/gp63-, gX-, or givirus deletion mutants. The PrV-specific CLTs were significantly less effective in lysing gi--infected targets than in lysing gI-/gp63-, gX-, or wild-type-infected targets. The in vitro secondary CTL response of lymphocytes obtained from either mice or pigs 6 or more weeks after immunization with a TK-mutant of PrV was also tested. Lymphocytes obtained from these animals were cultured with different glycoprotein-deficient mutants of PrV, and their cytolytic activities against wild-type-infected targets were ascertained. The importance of each of the nonessential viral glycoproteins in eliciting CTLs was assessed from the effectiveness of each of the virus mutants to stimulate the secondary anti-PrV CTL response. Cultures of both murine or swine lymphocytes that had been stimulated with gIII-virus contained only approximately half as many lytic units as did those stimulated with either wild-type virus, a gX-virus mutant, or a gl-/gp63-virus mutant. Thus, a large proportion of the PrV-specific CTLs that are induced by immunization with PrV of both mice and pigs are directed against gIll. Furthermore, glycoproteins gI, gp63, and gX play at most a minor role in the CTL response of these animals to PrV.
Pseudorabies virus (PrV; suid herpesvirus 1) is the etiologic agent of Aujeszky's disease, a disease that is lethal to young pigs and that causes important economic losses (8) . Because of the significant economic losses caused by this disease, vaccination of pigs with attenuated or killed vaccines is practiced in many countries. However, eradication of the disease has not as yet been achieved. A rational approach to the control of Aujeszky's disease requires an understanding of the immune response against infection with PrV and identification of the viral antigens responsible for eliciting a protective immune response. However, neither of these determinants is as yet well understood.
Evidence that infection with PrV elicits both humoral and cell-mediated immune responses is widely recognized (9, 10, 11, 42, 49) . A humoral immune response after experimental infection or vaccination of pigs with PrV has been detected that consists of virus-neutralizing antibodies, antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity, and antibodies capable of mediating complementmediated lysis of PrV-infected target cells (20, 21, 50, 51) . Much of the humoral neutralizing response in naturally and has also been detected after infection or vaccination of pigs with PrV (50, 51) . Furthermore, the presence of cytotoxic lymphocytes specific for cells infected with PrV in the draining lymph nodes of an intranasally infected pig has been reported (19) .
Envelope glycoproteins of PrV are known to be important in the induction of protective immunity against challenge with virulent PrV (14, 35) . Therefore, an understanding of the role that each of the envelope glycoproteins of PrV plays in cell-mediated immunity should help in the development of effective vaccines against PrV.
The aim of the experiments presented in this report was to study the CTL response of mice and pigs to nonessential envelope glycoproteins of PrV. This is of particular interest because vaccines deficient in these glycoproteins have been and are being developed. We present evidence that a large proportion of the PrV-specific CTLs in mice and in swine is directed against glycoprotein gIll, while a small proportion only (if any) of these CTLs is directed against glycoprotein gI, gp63, or gX.
MATERIALS AND METHODS
Cell cultures, virus mutants, and animals. Rabbit kidney and Madin-Darby bovine kidney cells were cultivated in Eagle synthetic medium containing 5% calf serum. L (H-2k) cells expressing the H-2Ld or H-2Dd molecule (a generous gift from James Forman, University of Texas Southwestern Medical Center at Dallas) were cultured in hypoxanthineaminopterin-thymidine medium supplemented with 5% fetal bovine serum, glutamine (1 mM), and gentamicin (50 ,ug/ml). mouse embryo fibroblasts and pig testis cells, respectively (at the second passage), with simian virus 40 L929 (H-2k) and PK(15) cells were purchased from The American Tissue Culture Collection. These cells were cultured in Dulbecco modified Eagle medium supplemented with 10% calf serum. Cells of the human erythroleukemia cell line K562, a gift from Jim Forbes (Vanderbilt University), were cultured in RPMI 1640 (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% calf serum. Murine lymphocytes were cultured in RPMI supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (GIBCO), N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; 10 mM), L-glutamine (2 mM), 2-mercaptoethanol (5 x 10' M), sodium pyruvate (2 mM), penicillin (100 U/ml), streptomycin (100 ,ug/ml), and tylosin (1 ,ug/ml)). Swine peripheral blood lymphocytes were cultured in complete RPMI supplemented as described above except that fetal bovine serum was substituted with CPSR-2 (Sigma Chemical Co., St. Louis, Mo.) at a concentration of 10% (vol/vol) (CPSR-RPMI).
PrV(Ka) is a strain that has been carried in our laboratory for more than 25 years. Isolation and characterization of the mutants defective in the glycoprotein genes encoding gI and gp63, gX, and gIll, used in this study, have been described (26) (27) (28) 41) . Mutants defective in the expression of thymidine kinase (TK-) were isolated from each as described previously (22 
RESULTS
PrV encodes at least eight glycoproteins (12) . The genes encoding six of these envelope glycoproteins, gI, gll, gIll, gp63, gpSO, and a secreted glycoprotein, gX, have been mapped and sequenced (25, 31-33, 38, 39, 46) . Of these, gI, glll, gp63, and gX are nonessential for virus growth in cell culture (1, 24, 32, 40, 47) gI-/gp63-, and gX--infected cells were used as targets at 6 or 8 h postinfection, at which times all cells showed similar degrees of susceptibility to antibody-and complement-mediated cell lysis.
Generation of PrV-specific CTLs in mice. To generate a PrV-specific cell-mediated immune response, DBA/2 mice were injected in the footpads with a TK-mutant of PrV(Ka).
Lymphocytes were isolated from the draining popliteal lymph node 6 days after injection and cultured for 3 days in the presence of either PrV-infected or uninfected, irradiated syngeneic splenocytes. Lymphocytes isolated from PrV-infected animals were able to lyse PrV-infected (but not uninfected) syngeneic target cells whether or not they had been stimulated with infected spleen cells; lymphocytes isolated from naive ani- , or mutant glll-(C). They were labeled with 51Cr and reacted at the indicated times for 1 h with anti-PrV serum (l), anti-gI MAb (*), or anti-gIll MAb (U), followed by incubation for 1 h with rabbit complement. The percent specific 51Cr release was ascertained. Background release at the end of the experiment was <25%. mals and cultured with PrV-infected spleen cells did not (Table 1) . Thus, a PrV-specific lytic activity was generated in the PrV-immunized animals which, under the experimental conditions used, did not require additional antigenic stimulation during culture in vitro, probably because of the presence of residual viral antigen in the lymphocyte culture. (Since the presence of live virus in the culture did not affect lysis, it appears that the effector cells are not susceptible to PrV infection.) In subsequent experiments, the lymphocytes were therefore not exposed to antigenic stimulation during culture in vitro before assay.
The lymphocytes isolated from the PrV-infected DBA/2 mice lysed PrV-infected syngeneic MESV (H-2d) cells but not allogeneic L929 (H-2k) cells (Fig. 2) . They are therefore MHC restricted. Furthermore, the cytotoxic cells lysed PrV-infected but not uninfected L cells expressing the H-2Ld but not the H-2Dd molecule (Fig. 2) . Thus, these cytotoxic cells were restricted by the H-2Ld but not by the H-2Dd molecule.
To further define the phenotype of the cells that mediate the lysis of the PrV-infected target cells, the effector cells were treated with complement and different antibodies against T-cell-specific cell surface antigens. Their lytic activity against PrV-infected syngeneic MESV cells was ascertained thereafter. Treatment of the effector cells with antibodies against the T-cell antigen Thy-1 or against the CTL phenotypic marker CD8 (Lyt-2) plus complement eliminated 70% of the lytic activity against PrV-infected cells (Fig. 3) . Treatment with antibodies against the helper T-cell phenotypic marker CD4 (L3T4) and complement, on the other hand, did not decrease the lytic activity of the effector cells. Thus, the PrV-specific cytotoxic cells have the cell surface phenotype of classical class I MHC-restricted CTLs, Thy-l+ L3T4-Lyt-2+ (43) .
Role of PrV glycoproteins in the PrV-specific CTL response of mice. To ascertain the role that each of the nonessential PrV glycoproteins plays as a target antigen for PrV-specific CTLs, we compared the ability of the anti-PrV CTLs to lyse syngeneic cells infected with wild-type PrV or with mutants of this virus that do not express either glycoprotein gI and gp63 (gI-/gp63-), gX (gX-), or gIII (gIII-). Using this approach, we consistently observed that at the same effector/target ratios, the percent specific lysis of cells infected with mutant gl-/gp63-or gX-was the same as that of cells infected with wild-type virus (Fig. 4A) . On the other hand, the effector/target ratio needed to obtain comparable lysis of gIII--infected cells was significantly higher. Effector/target ratios required to lyse 30% of the target cells varied some- To rule out the possibility that the higher number of effector cells required to achieve comparable lysis of gIIIinfected cells than of wild-type-infected cells is due to the lower susceptibility of the former to CTL-mediated lysis (because of a low level of expression of surface glycoproteins in gll-sinfected cells or because of the low intrinsic fragility of these cells), we simultaneously measured the susceptibility of the same target cells to anti-PrV antibodyand complement-mediated lysis. Lysis of all of the target cells by PrV-specific antiserum and complement was similar (Fig. 4B) . Thus, the target cells infected with mutantglIldid not appear to be less susceptible to lysis than were the target cells infected with the other mutants or with wild-type virus.
Since gl-/gp63--and gX--infected cells were as sensitive to CTL-mediated lysis as were wild-type-infected cells, our results would indicate that the PrV-specific CTLs against PrV-infected target cells are not directed against glycoproteins gI, gp63, and gX. On the other hand, because the gIII--infected targets were less susceptible to CTL-mediated lysis, it would appear that a significant proportion of the 
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PrV-reactive CTLs may be directed against glycoprotein glll. However, despite the fact that glIl--infected targets were as sensitive to antibody-and complement-mediated cell lysis as were targets infected with wild-type virus or with mutant gI-, we felt it necessary to further eliminate the possibility that a differential susceptibility of the target cells to lysis contributed to our results. We therefore used a different approach and tested the abilities of wild-type-and mutant-infected cells to stimulate in vitro a secondary CTL response against PrV-infected cells. The rationale behind this approach was that if a significant proportion of the PrV-specific memory CTLs is directed against a particular glycoprotein, the absence of this glycoprotein during induction of the secondary CTL response should generate a significantly lower number of lytic units. Since in this type of experiment the lytic activity of the different CTL populations is tested against the same target cells, possible differences in susceptibility of the target cells to lysis can be eliminated as a source of experimental error.
To obtain lymph node cell populations that would respond to secondary antigenic stimulation in vitro, peripheral lymph nodes were obtained from DBA/2 mice 6 to 8 weeks after they had been inoculated with PrV TK-. The isolation of lymph node cells was delayed until close to 2 months after inoculation because by this time CTL activity was not detectable unless the cells were restimulated with viral antigen during cultivation in vitro. The lymph node cells were cocultured with irradiated (2,500 R) syngeneic ASC that had been mock infected, infected with wild-type PrV, or infected with mutant gl-/gp63-, gIII-, or gX-. The cells were cultured for 5 days, and their lytic activity against syngeneic PrV(Ka)-infected MESV cells was tested in a 4-h 51Cr release assay (Fig. 5) .
As expected, only low levels of lytic activity were detected in lymphocyte cultures stimulated with mock-infected ASC, whereas lymphocyte cultures stimulated with any one of the PrV-infected ASC had substantial lytic activity against the PrV-infected MESV cells (Fig. 5) . The number of effector cells required to achieve 30% lysis of the target cells was similar when the lymphocyte cultures had been stimulated with ASC that had been infected with wild-type virus or with the double-deletion mutant gI-/gp63-. However, three times as many effector cells were required to achieve 30% specific lysis of the same PrV-infected target cells when the lymphocyte cultures had been cocultured with gIII--infected ASC. Similar results were obtained in several different experiments (Table 2) . In all cases, lymphocyte cultures stimulated with gIII--infected ASC generated a lower number of lytic units against PrV(Ka)-infected MESV cells than did cultures stimulated with ASC infected with either wild-type virus, gl-/gp63-, or gX-. Significant lytic activity against mock-infected MESV cells or against PrV-(Ka)-infected allogeneic L cells was not detected in any of the experiments (Table 2) .
To ensure that the lower ability of the gIl--infected ACS than of the wild-type-infected ACS to stimulate an anti-PrV lytic activity was not related to lower doses of mutant gIIIthan of wild-type virus with which the stimulator cells were infected (gIII-virus does not adsorb to its host cells as effectively as does gIII+ virus [41] ), the effect of adding increasing amounts of virus to the stimulator ASC-lymphocyte culture was ascertained. The lytic activity observed when the ASC-lymphocyte cultures were stimulated with mutant gIII-was lower than that obtained when the ASClymphocyte cultures were stimulated with wild-type virus over a large range of doses (Fig. 6) . Furthermore, the peak 106 per well) isolated from DBA/2 mice 6 weeks after footpad immunization with PrV TK-were cocultured for 5 days with irradiated syngeneic ASC (106 per well) that had been mock infected, infected with wild-type PrV(Ka), or infected with mutant gl-/gp63-or gIII-. The lytic activity of the effector cells was tested against 51Cr-labeled PrV-infected MESV cells in a 4-h 51Cr release assay. Lysis at an effector/target ratio of 100:1 of syngeneic mockinfected MESV cells was 10% and of allogeneic PrV-infected L929 cells was 9%, indicating the specificity and MHC restriction of the effector cell population. One lytic unit is the number of effector cells required to achieve 30% specific lysis. The number of lytic units in 106 cells was determined as described in the text. lysis occurred at similar doses for both. These results indicate that the lower induction of lytic activity by the gIII--infected stimulator cells was not related to the virus (antigen) dose. We conclude that the lower lytic activity of the lymphocyte cultures stimulated by mutant gIII-reflects the fact that a significant proportion of the secondary PrVspecific CTL response in DBA/2 mice is directed against glycoprotein gIll, i.e., that gIII is a major target antigen for PrV-specific CTLs. Glycoproteins gI, gp63, and gX, on the other hand, play at most a minor role in the reactivity of these cells.
Induction of porcine PrV-specific CTLs. Since swine are the natural host of PrV, it was of interest to determine whether results similar to those obtained with DBA/2 mice would also be obtained with swine. To test the MHCrestricted lytic activity of swine CTLs against PrV, autologous cell lines from two prospective donors of PrV-immune lymphocytes were established by transforming second-passage testis cells with simian virus 40 (PITSV cells). PBML isolated from these animals before immunization were infected with purified wild-type PrV(Ka) and cultured for 6 days, and their ability to lyse autologous PrV-infected or mock-infected cells was tested in a 4-h 51Cr release assay. The castrated pigs were then vaccinated by intramuscular injection of purified PrV(Ka) TK-. Four weeks after immunization and at intervals thereafter, the ability of cultured PBML obtained from the immunized animals to lyse PrVinfected cells was PBML were cultured in the absence of viral antigen, only background levels of lytic activity were generated (Table 3) . Stimulation with PrV of PBML isolated from the preimmune animals did not generate cells capable of lysing PrV-infected or mock-infected autologous cells (Table 3) . Thus, cytolytic cells against PrV-infected autologous cells were generated only when the PBML obtained from animals that had been vaccinated with PrV were stimulated in vitro with PrV. Since only background levels of lytic activity were detected against allogeneic cells infected with PrV (Fig. 7) , the lytic activity of the effector cells was restricted by MHC antigens. Furthermore, only background levels of lytic activity were detected against the natural killer (NK) target cell line K562 (Fig. 7) Virus Dose PFU/ml Virus Dose PFU/ml FIG. 6 . Ability of various doses of wild-type PrV(Ka) or of a virus mutant defective in the expression of glll to stimulate a murine anti-PrV secondary CTL response. Peripheral lymph node cells isolated from DBA/2 mice 6 weeks after footpad immunization with PrV(Ka) TK-were cultured as described in the legend to Fig. 5 with increasing concentrations of wild-type PrV (a) or of mutant glll-(A). After 5 days in culture, the effector cells were tested for lytic activity against syngeneic PrV-infected MESV cells in a 4-h 51Cr release assay. Effector/target ratios were 100:1 (A) and 33:1 (B). Lysis of mock-infected MESV cells or PrV-infected allogeneic L cells (H-2k) at a 100:1 ratio was <15%. specific against PrV were generated from PBML isolated from pig 30 as described in footnote a of Table 3 and tested in a 4-h 5"Cr release assay against the indicated target cells. Autologous cells were PITSV-30; allogenic cells were PK cells.
cells responsible for the lytic activity against autologous PrV-infected cells in the PBML population obtained from one of the immunized pigs (pig 30; pig 29 died of causes unrelated to infection with PrV) was ascertained (Fig. 8) . To this end, we determined the ability of antibodies against pig T-cell surface antigens PT4 (CD4) and PT8 (CD8) to deplete the lytic activity in the presence of complement (30) . PBML isolated from the immune animal were cultured for 6 days with purified PrV and treated with complement alone, with anti-PT4 antibody and complement, or with anti-PT8 anti- (Fig. 8) . Thus, the secondary anti-PrV cytotoxic cell response that was induced by PrV in PBML obtained from PrV-immune pigs was mediated by cells with the phenotype of porcine CTL, PT4-PT8+ (30) .
Role of the nonessential PrV envelope glycoprotein in porcine PrV-specific CTL response. To ascertain the role (if any) of the nonessential PrV envelope glycoproteins in the reactivity of porcine PrV-specific CTLs, the ability of purified populations of virus, each lacking a specific nonessential glycoprotein, to stimulate a secondary anti-PrV CTL response of porcine PBML was ascertained (Fig. 9) . Stimulation of cultures of PrV-immune pig PBML with either mutant gl-/gp63-or mutant gX-resulted in the generation of as many lytic units against PrV-infected autologous cells as did stimulation with wild-type virus. However, PBML cultures stimulated with purified gIll-contained only approximately half as many lytic units as did PBML cultures stimulated with wild-type virus (Fig. 9) . The induction of the lower number of lytic units by mutant glIl-than by wild-type virus was not due to a lower dose of gIII-antigen with which the PBML was inoculated. This was demonstrated by an experiment in which increasing amounts of wild-type virus and mutant gIII-were added to the PBML cultures to induce the secondary CTL responses (Fig. 10) stimulation during the in vitro culture period could be detected in mice for several weeks after inoculation. Our results therefore show that PrV, like many other viruses, induces a CTL response in mice.
Anti-PrV CTL could also be detected in PBML cultured with purified PrV (devoid of any detectable contaminating foreign proteins) that had been isolated from venous blood of PrV-immune pigs. Since the pathway of lymphocyte recirculation in the pig occurs mainly through the venous blood rather than through the efferent lymph as is the case in other species (3), memory CTLs should be present in peripheral venous blood in significant numbers. We show here that they indeed are; the lytic activity could be detected at the earliest The role of nonessential viral envelope glycoproteins in eliciting CTLs was assessed by using otherwise isogenic mutants of PrV that differ only in that each lacks a specific glycoprotein. In the murine system, we first compared the lytic activity of primary PrV-immune lymphocytes against cells infected with wild-type PrV or with one of three glycoprotein deletion mutants (gl-/gp63-, gX-, or gIII-).
Using this method, we observed that at the same effector/ target ratios, the percent specific lysis of gIII--infected target cells was consistently lower than that of wild-type PrV, gI-/gp63-, or gX--infected target cells. These observations indicated either that a significant proportion of the PrV-specific CTLs were directed against gIII or that cells To ensure that the lower effector/target ratio required to lyse wild-type-infected cells than to lyse gIII--infected cells was not due to a difference in the susceptibility of the target cells, we used an alternative approach. In these experiments, memory CTLs isolated from PrV-immune mice several weeks after immunization were stimulated in vitro with syngeneic ASC infected with wild-type PrV or with one of the three glycoprotein deletion mutants. The lytic activities of the different effector cells were then compared by using in all cases the same wild-type-infected target cells. The results obtained showed that the number of lytic units generated when the effector cells were stimulated with gIII--infected cells was smaller than that obtained after stimulation with wild-type-, glI-/gp63--, or gX--infected cells. The lower lytic activity obtained with gIII--infected stimulator cells held true for stimulator cells infected over a large range of multiplicities of gIII-. These findings indicate that a significant proportion of the PrV-specific CTLs produced by DBA/2 mice infected with PrV are directed against gIIl.
The finding that in DBA/2 mice gIII is a component of PrV that elicits a significant fraction of the CTL response was corroborated by the results obtained in swine. Thus, in two different species, one of the major proteins of PrV that elicited a CTL response was glycoprotein gIII. Glycoprotein gIll of PrV is a homolog of glycoprotein gC of herpes simplex virus (HSV) type 1 (39) , which has been shown to be a dominant viral target antigen in HSV-specific CTL response in mice (7) . Our finding that a significant proportion of the CTL response to PrV is directed against glycoprotein gIll is thus consistent with the results obtained with HSV. A shortcoming of our experiments is that the response to gIll of only one pig was ascertained, and it is possible that individual pigs may react somewhat differently. Indeed, recent reports have appeared showing that in different strains of mice, a given viral protein may or may not elicit a major CTL response (13, 48) . However, because we have obtained similar results with both DBA/2 mice and swine, it seems likely that gIII is one of the main PrV antigens that induces a cellular immune response.
Although we have concentrated on analyzing the role of nonessential viral glycoproteins in the immune response to PrV and have shown that glycoprotein gIll is important whereas gI, gp63, and gX are not, it is clear that other proteins may be equally important. Thus, analyses of the responses to other viruses have suggested that CTLs may be directed not only against structural but also against nonstructural proteins (23, 36, 52) . For example, the immediateearly gene products of human and mouse cytomegaloviruses as well as of HSV type 1 have been shown to constitute major target antigens for antiviral CTL (6, 16, 37) . Therefore gIII is probably only one of several viral proteins that elicit a cellular immune response.
It is interesting that a major part of the neutralizing antibodies present in serum obtained from pigs convalescing from PrV infection is directed against glycoprotein gIII (1; F. Zuckermann et al., manuscript in preparation). In view of our finding that gIII appears to be the viral component that elicits a strong CTL response, it appears that gIII may play a central role in the induction of immunity and that therefore it is likely to be important in the induction of a protective immune response. It is clear, therefore, that it should be included as a component of any vaccine used in the control of Aujeszky's disease.
